Published in Biotech Law Weekly, November 19th, 2004
The results of the company's International Generics, Active Pharmaceutical Ingredients and Animal Health businesses were at or above expectations. In addition, the company expects to report strong third quarter free cash flow and debt to be below second quarter 2004 levels.
The company will update its guidance for the full year...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.